ClinicalTrials.gg
CompletedNCT05654831Updated Jul 17, 2024

FTIH of ECC5004 in Healthy and Diabetic Participants

A Phase 1 interventional study of Placebo and ECC5004 in Type 2 Diabetes Mellitus, sponsored by Eccogene. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Eccogene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Enrollment
8th of 18
69 · median 57
Started
2022
the only one that year
Phase 1
11 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
4 of 18
Eccogene

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is the only one that started in 2022, is one of 11 in phase 1, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC5004 in healthy participants and in patients with Type 2 Diabetes Mellitus

Read the detailed description

This study will be conducted in two cohorts of Single Ascending Dose (SAD) with a dose range from 1mg to 300mg, and in four cohorts of Multiple Ascending Dose (MAD) with a dose range of 10mg to 150mg to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC5004 in Healthy Participants and in Patients with Type 2 Diabetes Mellitus

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants of non-
  • Age of 18 to 65 years
  • of 18.0 to 32.0 kg/m2
  • ≤ 6.0%
  • Female participants who are , confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or agree to practice true abstinence
  • Male participants agree to use , or agree to practice true abstinence
  • No findings in physical examination, 12-lead (ECG), vital sign measurements, laboratory tests, or medical/psychiatric history
  • Able to understand and sign and date

Additional Inclusion Criteria for Part 2 (MAD)

  • Diagnosed Type 2 Diabetes Mellitus of 18 to 70 years of age inclusive
  • Type 2 Diabetes Mellitus with lifestyle modification only or with stable dose of metformin for ≥ 2 months prior to the study treatment
  • BMI of 24.0 to 40.0 kg/m2 with a minimum body weight of 50.0 kg (110 lbs)
  • HbA1c ≥ 7.0% and ≤ 10.5%, and fasting plasma glucose ≤ 270 mg/dL
  • Blood pressure (BP) with or without medication: Systolic BP ≤ 160 mmHg, AND Diastolic BP ≤ 100 mmHg
  • Not taking any active treatment regimen

Exclusion criteria

Exclusion Criteria:

  • Concomitant participation in any study of any nature
  • Blood loss of non-physiological reasons ≥ 200 ml (i.e. trauma, blood collection, blood donation) within 2 months prior to the first dose of study drug, or plan to donate blood during this trial and within 1 month after the last dosing
  • Unable to refrain from taking any non-metformin anti-diabetic medication including insulin within ≥ 3 months prior to the study treatment
  • Serum calcitonin > 20 ng/L
  • acute or chronic medical conditions or diseases of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic systems
  • Diagnosis of T1DM or secondary forms of diabetes
  • Individual or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia 2 (MEN2), or suspected MTC
  • History of pancreatitis
  • Significant allergic reaction to active ingredients or of the study drug.
  • Any clinically significant abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
69 participants (actual)

Study arms

  • Placebo comparator
    SAD Cohorts 1 to 2: Participants receiving Placebo

    Participants in each SAD cohort will be randomized to receive placebo.

    Drug: Placebo

  • Experimental
    SAD Cohorts 1 to 2: Participants receiving ECC5004

    Participants in each SAD cohort will be randomized to receive up to 4 escalating doses of ECC5004 ranging from 1 mg to 300 mg.

    Drug: ECC5004

  • Placebo comparator
    MAD Cohorts 1 to 4: Participants receiving Placebo

    Participants will be randomized to receive a once-daily dose of placebo for 28 days.

    Drug: Placebo

  • Experimental
    MAD Cohorts 1 to 4: Participants receiving ECC5004

    Participants will be randomized to receive a once-daily dose of 1 of 4 escalating doses of ECC5004 ranging from 10 mg to 150 mg for 28 days.

    Drug: ECC5004

Interventions

  • DrugPlacebo

    Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.

  • ECC5004 will be administered as oral tablet(s) during each dosing day.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations

    Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 35

Secondary outcomes

  1. Pharmacokinetic Parameters: AUC0-24

    AUC from time 0 to 24 hour dosing interval

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  2. Pharmacokinetic Parameters: AUC0-tlast

    AUC from time 0 to the time of last quantifiable non-zero concentration

    Time frame: SAD: Up to Day 3

  3. Pharmacokinetic Parameters: AUC0-tau

    AUC over a dosing interval from time 0 to time of last quantifiable concentration

    Time frame: MAD: Up to Day 30

  4. Pharmacokinetic Parameters: AUC0-infinity

    AUC from time 0 extrapolated to infinity

    Time frame: SAD: Up to Day 3

  5. Pharmacokinetic Parameters: Cmax

    Maximum observed plasma concentration

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  6. Pharmacokinetic Parameters: C24

    Observed concentration at 24 hours post dose

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  7. Pharmacokinetic Parameters: Ctau

    Observed concentration at the end of the dosing interval

    Time frame: MAD: Up to Day 30

  8. Pharmacokinetic Parameters: tmax

    Time of the maximum observed plasma concentration

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  9. Pharmacokinetic Parameters: tlag

    Lag time (time delay between dosing and first observed plasma concentration)

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  10. Pharmacokinetic Parameters: t1/2

    Apparent terminal elimination half-life

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  11. Pharmacokinetic Parameters: Clast

    Last measurable non-zero concentration

    Time frame: SAD: Up to Day 3

  12. Pharmacokinetic Parameters: tlast

    Time of last measurable non-zero concentration

    Time frame: SAD: Up to Day 3

  13. Pharmacokinetic Parameters: CL/F

    Apparent Clearance

    Time frame: SAD: Up to Day 3 and MAD: Up to Day 30

  14. Pharmacodynamic Parameters: AUC0-4 for glucose

    AUC from time 0 to 4 hour dosing interval

    Time frame: MAD: Up to Day 30

  15. Pharmacodynamic Parameters: AUC0-4 for insulin

    AUC from time 0 to 4 hour dosing interval

    Time frame: MAD: Up to Day 30

  16. Pharmacodynamic Parameters: AUC0-4 for glucagon

    AUC from time 0 to 4 hour dosing interval

    Time frame: MAD: Up to Day 30

  17. Pharmacodynamic Parameters: AUC0-4 for C-peptide

    AUC from time 0 to 4 hour dosing interval

    Time frame: MAD: Up to Day 30

  18. Pharmacodynamic Parameters: Fasting plasma glucose

    Change from baseline

    Time frame: MAD: Up to Day 30

  19. Pharmacodynamic Parameters: Mean daily glucose

    Change from baseline

    Time frame: MAD: Up to Day 30

  20. Pharmacodynamic Parameters: Body Weight and Waist Circumference

    Change from baseline

    Time frame: MAD: Up to Day 30

  21. Pharmacodynamic Parameters: Fasting plasma glucose homeostatic model assessment

    Fasting plasma glucose homeostatic model assessment

    Time frame: MAD: Up to Day 30

  22. Pharmacodynamic Parameters: Fasting plasma insulin homeostatic model assessment

    Fasting plasma insulin homeostatic model assessment

    Time frame: MAD: Up to Day 30

07

Study locations

1 site
  • Eccogene Investigational Site
    Anaheim, California 92801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Nov 2023, 11 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 11 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Dec 1, 2022
Primary completionActual
Nov 1, 2023
CompletionActual
Nov 1, 2023
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05654831
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Dec 1, 2022
Primary completion
Nov 1, 2023
Completion
Nov 1, 2023
Last update
Jul 17, 2024

Study contacts

Eccogene
study director · Eccogene Clinical Trials

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion